Poor
Mostly Aligned
Patient Risk:
Info
Summary
Only the specific 'suicidal thoughts and behaviors risk' theme is supported by the provided label excerpts; most other medication-brand, dosing/administration, adverse reaction, and safety-related claims are not verifiable or are outside the supplied label content.
Category Scores
Accurate Statements
More serious side effects of escitalopram oxalate can include suicidal thoughts.
Supported by the provided label excerpts in 5.1 and 17 (Warnings/Boxed Warning and patient counseling regarding increased risk of suicidal thoughts and behaviors).
Unsupported Statements
Escitalopram oxalate is marketed under the brand name Lexapro.
Not supported or evidenced by the supplied FDA label excerpts.
Escitalopram oxalate is marketed under the brand name Cipralex.
Not supported or evidenced by the supplied FDA label excerpts.
Escitalopram oxalate is marketed under the brand name Seroplex.
Not supported or evidenced by the supplied FDA label excerpts.
Different pharmaceutical companies may manufacture and market the same active ingredient under various brand names.
Not supported or evidenced by the supplied FDA label excerpts.
Different brand names may exist for the same drug when patent protections expire, allowing generic manufacturers to produce and sell versions of the medication.
Not supported or evidenced by the supplied FDA label excerpts.
A drug may be marketed under different brand names in different countries or regions to comply with local regulations and marketing strategies.
Not supported or evidenced by the supplied FDA label excerpts.
The patent for Lexapro has expired.
Not supported or evidenced by the supplied FDA label excerpts.
The expiration of the Lexapro patent has allowed the introduction of generic versions of escitalopram oxalate into the market.
Not supported or evidenced by the supplied FDA label excerpts.
Brand-name drugs and generic equivalents contain the same active ingredient.
Not supported or evidenced by the supplied FDA label excerpts.
Brand-name and generic drugs are manufactured to meet the same standards for safety, effectiveness, and quality.
Not supported or evidenced by the supplied FDA label excerpts.
The primary differences between brand-name and generic escitalopram products typically lie in inactive ingredients (fillers, binders, coatings) and price.
Not supported or evidenced by the supplied FDA label excerpts.
Generic versions are generally less expensive than brand-name counterparts.
Not supported or evidenced by the supplied FDA label excerpts.
Escitalopram oxalate is a selective serotonin reuptake inhibitor (SSRI) antidepressant.
Not supported or evidenced by the supplied FDA label excerpts.
Escitalopram oxalate is used to treat major depressive disorder in adults and adolescents 12 years of age and older.
Not supported or evidenced by the supplied FDA label excerpts.
Escitalopram oxalate is used to treat generalized anxiety disorder in adults.
Not supported or evidenced by the supplied FDA label excerpts.
Common side effects of escitalopram oxalate can include nausea.
Not supported or evidenced by the supplied FDA label excerpts.
Common side effects of escitalopram oxalate can include insomnia.
Not supported or evidenced by the supplied FDA label excerpts.
Common side effects of escitalopram oxalate can include ejaculation disorder.
Not supported or evidenced by the supplied FDA label excerpts.
Common side effects of escitalopram oxalate can include fatigue.
Not supported or evidenced by the supplied FDA label excerpts.
Common side effects of escitalopram oxalate can include increased sweating.
Not supported or evidenced by the supplied FDA label excerpts.
More serious side effects of escitalopram oxalate can include changes in mood.
Not supported or evidenced by the supplied FDA label excerpts.
More serious side effects of escitalopram oxalate can include serotonin syndrome.
Not supported or evidenced by the supplied FDA label excerpts.
Numerous pharmaceutical companies produce generic versions of escitalopram oxalate.
Not supported or evidenced by the supplied FDA label excerpts.
Contradictions
Important Omissions
If the response aimed to discuss boxed warning content comprehensively, it omitted label-specific details present in 5.1/17 such as monitoring instructions for all antidepressant-treated patients, counseling family/caregivers, and considering changing the therapeutic regimen (including possibly discontinuing) in patients with emergent suicidal thoughts/behaviors.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Only the suicidal thoughts/behaviors risk was supported by the provided label excerpts; other included safety/side-effect claims were not supported by the supplied label text and therefore could mislead, though no direct contradiction to the provided label excerpts was identified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Most claims (brand names, patent/generic rationale, indications, and adverse effects such as nausea/insomnia/serotonin syndrome) are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict statements to what is supported by the provided label sections; for safety, include the specific label-directed monitoring/counseling language related to suicidal thoughts and behaviors (5.1, 17) rather than adding additional side effects not evidenced in the supplied text.